Cover Image

PAPERBACK
$162.25



View/Hide Left Panel

Page 449

Appendix
E
Use of Pharmacokinetics to Extrapolate From Animal Data to Humans

Introduction

In classical toxicology, the issue of extrapolation of (usually) animal data to human applications is phrased as:

Dose to dose (usually high dose in animals to low dose for applications).

Route to route (e.g., ingestion vs. inhalation).

Species to species (animal or cell culture to humans).

Pharmacokinetics (PK) can aid in understanding information and in predicting outcomes with respect to the absorption, disposition, metabolism, and excretion of chemicals. Traditionally, analysis has been done empirically, with direct use of the data at hand, and possibly with the aid of simple mathematical models that use overall mass balances. More recently, compartmental models based on chemical transfer in and out of body organs, or even portions of organs, have been developed to describe and predict relationships between administered dose and biologically effective concentrations of parent compounds or metabolites in critical target tissues. These models, which are based on the anatomy and physiology of mammals and use the vast amount of published comparative physiologic data, are known as physiologically based pharmacokinetic (PBPK) models. Details are given in a review by Bischoff (1987).

Each of the three main kinds of extrapolation is briefly described below.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement



Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 449
Page 449 Appendix E Use of Pharmacokinetics to Extrapolate From Animal Data to Humans Introduction In classical toxicology, the issue of extrapolation of (usually) animal data to human applications is phrased as: • Dose to dose (usually high dose in animals to low dose for applications). • Route to route (e.g., ingestion vs. inhalation). • Species to species (animal or cell culture to humans). Pharmacokinetics (PK) can aid in understanding information and in predicting outcomes with respect to the absorption, disposition, metabolism, and excretion of chemicals. Traditionally, analysis has been done empirically, with direct use of the data at hand, and possibly with the aid of simple mathematical models that use overall mass balances. More recently, compartmental models based on chemical transfer in and out of body organs, or even portions of organs, have been developed to describe and predict relationships between administered dose and biologically effective concentrations of parent compounds or metabolites in critical target tissues. These models, which are based on the anatomy and physiology of mammals and use the vast amount of published comparative physiologic data, are known as physiologically based pharmacokinetic (PBPK) models. Details are given in a review by Bischoff (1987). Each of the three main kinds of extrapolation is briefly described below.

OCR for page 449
Page 450 Dose to Dose PBPK permits reasonable extrapolation from one dose to another, if adequate information on physicochemical properties, physiology, pharmacology, and biochemistry is available. That is not often the case, with less being known as one moves along the list from physiochemical properties to biochemistry; however, PBPK models clearly reveal what data they require and thus what experiments will be needed to make them useful. If the dynamic processes modeled by the PBPK approach are all directly proportional to administered concentrations, then the extrapolation can be relatively straightforward. However, this is not often the case, especially at higher doses, where saturation of metabolic or clearance processes can occur. Despite those difficulties, there are many examples in the literature where useful PBPK analyses have been undertaken. Although PBPK analyses do not always directly address the question of pharmacodynamics (how the biologically effective dose to a critical target tissue is related to toxic response in that tissue), such analyses might provide insight pertinent to this question. Route to Route Two broad categories of route-specific toxicity need to be considered: "noncorrosive" and "corrosive." In the former, a chemical enters the body by some route and exerts its effect in the interior of the body; it must enter the blood circulation before it has its effect. In the latter, a very active chemical can have a direct effect at the point of entry, such as high levels of formaldehyde in the case of the rat, nitric acid on skin, or ethylene dibromide at the tip of a gavage tube. Some compounds, such as ethylene dibromide, can be both corrosive and noncorrosive. Most toxicants are noncorrosive, and knowledge of relevant physiology and pharmacology can permit extrapolation between routes of exposure, because the important information is the concentration in the blood and the transport to and uptake at the site of action. There could still be route-to-route differences, e.g., if the peak concentration after exposure determines toxicity. For example, absorption might be faster (and thus the peak higher) for intravenous than for oral exposure. PBPK models are useful, because they permit estimation of peak concentrations. Species to Species Species-to-species extrapolation is one of the most useful aspects of PBPK, because all mammals have the same macrocirculatory anatomy and much is known about the comparative dimensions of their physiologic characteristics—organ volumes, blood flow rates, some clearances, etc. The basic data are usual-

OCR for page 449
Page 451 ly presented as a function of body weight raised to some fractional power, Wb, with b = 0.7-1.0 (so-called "allometric scaling"). This aspect is relatively straightforward. However, other aspects can be more complicated, particularly those involving metabolism. For instance, there might be qualitative differences between species, such as the presence or absence of a given enzyme, that would result in a (potentially dose-dependent) difference in metabolic capacity and make their metabolism different.

OCR for page 449